Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$35.99

0.5 (1.41%)

07:42
02/07/18
02/07
07:42
02/07/18
07:42

GlaxoSmithKline says 2018 adjusted EPS growth uncertain due to Advair

CEO Emma Walmsley said: ""Looking ahead, in 2018 we could see a potential generic version of Advair in the US and our 2018 guidance reflects this. With the sales momentum we anticipate from new and recent launches and focused improvements in operating performance we are increasingly confident in our ability to deliver mid to high single digit growth in Adjusted EPS CAGR in 2016-2020 at 2015 CER. Cash generation also continues to be a key focus with free cash flow for the year improving to GBP 3.4B. We met our commitment to pay a total dividend of 80p for 2017 and continue to expect to pay 80p for 2018." The Group expects to make continued progress in 2018, although the expectation for Adjusted EPS growth is impacted by a number of factors including, in particular, uncertainties relating to the timing and extent of potential generic competition to Advair in the US. In the event that no substitutable generic competitor to Advair is introduced to the US market in 2018, the Group expects 2018 Adjusted EPS growth of 4 to 7% at CER. This is based on an expected decline in 2018 US Advair sales of 20-25% at CER. In the event of a mid-year introduction of a substitutable generic competitor to Advair in the US, the Group expects full year 2018 US Advair sales of around GBP 750 million at CER, with Adjusted EPS flat to down 3% at CER. The effective tax rate for 2018 is expected to be approximately 19-20% of Adjusted profits after the impact of US tax reform which is expected to benefit the Group effective tax rate by two to three percentage points. If exchange rates were to hold at the average rates for January 2018 for the rest of 2018, the estimated negative impact on full-year 2018 Sterling turnover growth would be around 4% and if exchange gains or losses were recognized at the same level as in 2017, the estimated negative impact on 2018 Sterling Adjusted EPS growth would be around 6%.

  • 07

    Feb

  • 25

    Mar

  • 23

    Apr

GSK GlaxoSmithKline
$35.99

0.5 (1.41%)

01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis upgraded GlaxoSmithKline to Overweight from Equal Weight and raised his price target for the shares to GBP 16.50 from GBP 14.50. The analyst believes concerns are now reflected in the valuation and consensus expectations while HIV and shingles offer "sustainable drivers of mid-term growth."
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.

TODAY'S FREE FLY STORIES

FIT

Fitbit

$5.93

0.22 (3.86%)

15:00
08/20/18
08/20
15:00
08/20/18
15:00
Options
Fitbit calls active as shares extend gains »

Fitbit calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

MMM

3M

$204.54

-0.27 (-0.13%)

, SGMS

Scientific Games

$30.45

0.85 (2.87%)

14:53
08/20/18
08/20
14:53
08/20/18
14:53
Hot Stocks
3M announces filing of touch screen technology patent infringement lawsuit »

3M (MMM) and 3M…

MMM

3M

$204.54

-0.27 (-0.13%)

SGMS

Scientific Games

$30.45

0.85 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPY

Brookfield Property

$19.94

-0.15 (-0.75%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Conference/Events
Brookfield Property management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

LCI

Lannett

$5.40

-8.1 (-60.00%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

AABA

Altaba

$69.92

1.74 (2.55%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Options
Altaba Inc options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$20.26

0.31 (1.55%)

14:47
08/20/18
08/20
14:47
08/20/18
14:47
Conference/Events
Summit Materials management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

, ANDV

Andeavor

$147.76

2.82 (1.95%)

14:46
08/20/18
08/20
14:46
08/20/18
14:46
Hot Stocks
FTC approves Alimentation Couche-Tard sale of two Minnesota fuel stations »

The Federal Trade…

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

ANDV

Andeavor

$147.76

2.82 (1.95%)

ANCUF

Alimentation Couche-Tard

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$15.94

0.61 (3.98%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHII

PHI, Inc

$8.59

0.09 (1.06%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Hot Stocks
Alesia Value fund reports 4.7% stake in PHI »

On August 20,Alesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$216.05

-1.6 (-0.74%)

14:41
08/20/18
08/20
14:41
08/20/18
14:41
Periodicals
Breaking Periodicals news story on Apple »

Apple planning revamped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHVF

MGM China

$0.00

(0.00%)

14:36
08/20/18
08/20
14:36
08/20/18
14:36
Upgrade
MGM China rating change  »

MGM China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
The Fed has become an unexpected focus »

The Fed has become an…

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
Canada wholesale preview »

Canada wholesale preview:…

CTWS

Connecticut Water

$69.10

0.1 (0.14%)

14:34
08/20/18
08/20
14:34
08/20/18
14:34
Hot Stocks
PURA approves rate settlement agreement for Connecticut Water »

Connecticut Water Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$30.38

-0.095 (-0.31%)

14:30
08/20/18
08/20
14:30
08/20/18
14:30
Conference/Events
Williams management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

AMZN

Amazon.com

$1,880.70

-1.24 (-0.07%)

14:29
08/20/18
08/20
14:29
08/20/18
14:29
Periodicals
Amazon hires well-known cardiologist amid push into health, CNBC says »

Amazon has hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AMCX

AMC Networks

$61.70

1.28 (2.12%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
AMC Networks management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

OSPR

Osprey Energy Acquisition

$11.27

0.065 (0.58%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
Osprey Energy Acquisition to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PPG

PPG

$109.64

1.23 (1.13%)

14:24
08/20/18
08/20
14:24
08/20/18
14:24
Conference/Events
PPG management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

NFLX

Netflix

$330.55

13.77 (4.35%)

14:21
08/20/18
08/20
14:21
08/20/18
14:21
Technical Analysis
Technical Take: Netflix may test downtrend resistance line »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/20/18
08/20
14:17
08/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$5.35

-8.15 (-60.37%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

MBI

MBIA

$10.78

-0.22 (-2.00%)

14:15
08/20/18
08/20
14:15
08/20/18
14:15
Options
MBIA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$30.79

0.05 (0.16%)

14:08
08/20/18
08/20
14:08
08/20/18
14:08
Hot Stocks
SEC says Merrill Lynch to pay $8.9M to settle charges of undisclosed conflict »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.